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 Clinical isolates of M. tuberculosis were collected from TB 
patients at National TB Center of the Republic of 
Kazakhstan, Almaty 
 
 Drug susceptibility testing of M.tuberculosis  was 
determined by absolute concentration method on solid 
Lowenstein-Jensen medium and by using the BACTEC-
MGIT 960 Mycobacteria Growth Indicator Tube (BD 
Diagnostic Systems, USA) system 
 
 Spoligotyping was performed on DNA by using the standard 
method [4] using a reverse dot-blot spoligotyping 
commercially available kit 
 The whole genome sequencing of 20 M.tuberculosis clinical 
isolates from TB patients with different drug resistance (8 
MDR, 3XDR, 1 mono-resistant, 1 poly-resistant, 7 
susceptible) were performed by NGS platform Roche 454 
GS FLX+ according to standard protocols 
  
 
 Complete genomes assembling was performed by using 
NEWBLER de novo assembler (454 Life Sciences, 
Branford, CT) 
 
 Alignment and mapping of sequences was performed on 
reference strain of M.tuberculosis H37Rv (NC_000962.3, 
GCF_000195955.2) by using the GS Reference Mapping 
(454 Life Sciences, Branford, CT) 
 
 Comparative analysis of genomic variants among isolates 
was performed using Venn diagram 
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 The aim of this study is whole genome sequencing of M.tuberculosis clinical isolates with 
different drug susceptibility, the study of genetic markers of drug resistant TB and 
comparative analysis between the M.tuberculosis strains 
 
 Most of the studied isolates of M. 
tuberculosis (18) are W-Beijing family 
strains (East Asian), only two isolates 
belongs to families T (Euro-American) and 
MANU-1 (Indo-Oceanic) 
 
 
 International «Tuberculosis Drug 
Resistance Mutation Database» was 
analyzed to study the genetic loci involved 
in the resistance to basic anti-TB drugs. As 
a result of the analysis the most common 
mutations in 37 genes associated with 
drug resistance to 9 basic anti-TB drugs 
were selected 
 
 
 Genetic mutations in genes associated 
with drug resistance of M.tuberculosis 
were analyzed. All detected genomic 
variants with single nucleotide 
polymorphisms, insertions, deletions for 
each clinical isolates of M.tuberculosis 
indicating the description of the gene and 
protein, the positions on reference genome 
H37Rv, deep coverage of gene were 
prepared 
 
 
 Three main groups for comparative 
bioinformatics analysis were chosen – 
susceptible, MDR and XDR. 1018 genomic 
loci were identified as a common for all 
three study groups. The major parts of 
these genomic variants are found in “core” 
genes that necessary for mycobacteria life-
sustaining activity 
  
 
 45 and 33 unique genetic loci were found 
between МТВ-07-002 and МТВ-06-003, 
also between МТВ-07-002 and МТВ-07-
006, respectively 
 
 
 
 Several genomic variants have been 
detected in four genes PE_PGRS24, 
PPE24, PPE5, PE_PGRS56 which are 
typical for MDR and XDR isolates and 
belong to genes of protein family PE/PPE 
specific for species of Mycobacteria only 
 
 
 The mutations specific to MDR and XDR 
groups of M.tuberculosis isolates can be 
one of the additional virulence factors that 
may provide an advantage in host-
pathogen interaction 
 
 20 whole genomes of M.tuberculosis with different drug resistance profiles were sequenced 
using Roche GS FLX+ platform.  
 The structure of the M.tuberculosis strains genotypes determined by spoligotyping. The 
results of genotyping M.tuberculosis strains showed the prevalence of M.tuberculosis W-
Beijing (83,3%) strains among studied clinical isolates.  
 Four common genetic loci were found only in MDR and XDR isolates (genes PE_PGRS24, 
PPE24, PPE5, PE_PGRS56), that were not found in other isolates. Proteins of this family of 
genes may play a role of virulence factors and contribute to a successful infection.  
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  Worldwide in 2016, around 10.4 million 
people were diagnosed with TB among 
which 1.7 million died [1]. 
 
 
 Despite the progress in decreasing the 
global incidence of drug-susceptible TB, 
multidrug-resistant (MDR) and extensively 
drug-resistant (XDR) tuberculosis in the 
past decade led to decreased efficiency of 
chemotherapy. However, the rate of drug-
resistant TB increases annually, especially 
multidrug-resistant TB (MDR TB) [1]. 
 
 
  In Kazakhstan, the incidence of TB in 
2016 was 52.7 cases per 100,000 and the 
mortality rate was 3.4 per 100,000 [2].  
 
 
  The incidences of drug resistance, 
especially multidrug-resistant (MDR) TB, 
are increasing last 5 years in Kazakhstan 
[2].  
  
 
  27 countries relate to high MDR-TB 
burden countries according WHO data, 14 
of them in the European region, including 
Kazakhstan [1]. 
 
 
  At the moment in many countries around 
the world noted the spread of Beijing 
family strains of M.tuberculosis which 
associated with a high risk of drug 
resistance. 
 
 
  Beijing/W of Mycobacterium tuberculosis  
strains are the most virulent and 
prevalent among young individuals. 
 
 
  This genotype is widely distributed in 
many parts of the world, including areas 
where it was not found previously [3]. 
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Anti-TB drugs Gene locus Gene 
AMINOGLYCOSIDES 
(KANAMYCIN / 
CAPREOMYCIN / AMIKACIN / 
VIOMYCIN) 
MTB000019, Rv1694 rrs, tlyA  
ETHAMBUTOL Rv0340, Rv0341, Rv0342, Rv0343, 
Rv1267c, Rv3124, Rv3125c, Rv3126, 
Rv3264c, Rv3266c, Rv3793, Rv3794, 
Rv3795 
iniB, iniA, iniC, embR  
ETHIONAMIDE Rv1483, Rv1484, Rv3854c mabA, inhA, ethA  
FLUOROQUINOLONES Rv0005, Rv0006 gyrB, gyrA   
ISONIAZID Rv0129c, Rv0340, Rv0341, Rv0342, 
Rv0343, Rv1483, Rv1484, Rv1592c, 
Rv1772, Rv1854c, Rv1908c, 
Rv1909c, Rv2242, Rv2243, Rv2245, 
Rv2247, Rv2427a, Rv2428, Rv2846c, 
Rv3139, Rv3566c, Rv3795 
fbpC, iniB, iniA, iniC, 
mabA, inhA, ndh, 
katG, furA, srmR, 
fabD, kasA, accD6, 
oxyR, aphC, efpA, 
fadE24, nhoA, embB   
PARA-AMINOSALISYLIC ACID Rv2764c thyA  
PYRAZINAMIDE Rv2043c pncA  
RIFAMPICIN Rv0667, Rv3795 rpoB, embB   
STREPTOMYCIN MTB000019, Rv0682, Rv3919c rrs, rpsL, gidB   
MTB-07-007 
Locus Gene Protein / product 
The starting 
position in the 
reference genome 
Nucleotide  
Genomic 
variant 
Rv0006 gyrA DNA gyrase subunit A 7582 A C 
Rv0006 gyrA DNA gyrase subunit A 7585 G C 
Rv0006 gyrA DNA gyrase subunit A 9304 G A 
Rv0006 gyrA DNA gyrase subunit A 11820 C G 
Rv0667 rpoB 
DNA-directed RNA polymerase 
subunit beta 764666 G A 
Rv0682 rpsL 30S ribosomal protein S12 781687 A G 
Rv0682 rpsL 30S ribosomal protein S12 791249 C T 
Rv1267c embR transcriptional regulator EmbR 1416222 A G 
Rv1267c embR transcriptional regulator EmbR 1416232 A G 
Rv1592c Rv1592c hypothetical protein 1803265 G A 
Rv1694 tlyA 
16S/23S rRNA (cytidine-2'-O)-
methyltransferase TlyA 1924008 G A 
Rv1908c katG catalase-peroxidase 2155168 C G 
Rv1908c katG catalase-peroxidase 2158109 T C 
Rv2243 fabD 
malonyl CoA-acyl carrier protein 
transacylase 2517129 A G 
Rv2243 fabD 
malonyl CoA-acyl carrier protein 
transacylase 2521342 T C 
Rv2247 accD6 
acetyl-/propionyl-CoA 
carboxylase subunit beta 2521428 A G 
Rv2247 accD6 
acetyl-/propionyl-CoA 
carboxylase subunit beta 2522955 T G 
Rv3793 embC arabinosyltransferase C 4243346 A G 
Rv3794 embA arabinosyltransferase A 4243460 C T 
Rv3794 embA arabinosyltransferase A 4248003 A G 
Rv3795 embB arabinosyltransferase B 4250747 TG - 
Rv3919c gid 
rRNA small subunit 
methyltransferase G 4407927 T G 
Rv3919c gid 
rRNA small subunit 
methyltransferase G 4408923 C T 
 Example of detected genomic variants  
for clinical  isolate MTB-07-007 
